JP2019514895A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514895A5
JP2019514895A5 JP2018555682A JP2018555682A JP2019514895A5 JP 2019514895 A5 JP2019514895 A5 JP 2019514895A5 JP 2018555682 A JP2018555682 A JP 2018555682A JP 2018555682 A JP2018555682 A JP 2018555682A JP 2019514895 A5 JP2019514895 A5 JP 2019514895A5
Authority
JP
Japan
Prior art keywords
seq
sequence
epitope
peptide
cst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514895A (ja
JP7320947B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059302 external-priority patent/WO2017182528A1/en
Publication of JP2019514895A publication Critical patent/JP2019514895A/ja
Publication of JP2019514895A5 publication Critical patent/JP2019514895A5/ja
Priority to JP2021200876A priority Critical patent/JP2022022423A/ja
Application granted granted Critical
Publication of JP7320947B2 publication Critical patent/JP7320947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555682A 2016-04-19 2017-04-19 新規な免疫原性CD1d結合ペプチド Active JP7320947B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021200876A JP2022022423A (ja) 2016-04-19 2021-12-10 新規な免疫原性CD1d結合ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16166054.3 2016-04-19
EP16166054 2016-04-19
PCT/EP2017/059302 WO2017182528A1 (en) 2016-04-19 2017-04-19 Novel immunogenic cd1d binding peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021200876A Division JP2022022423A (ja) 2016-04-19 2021-12-10 新規な免疫原性CD1d結合ペプチド

Publications (3)

Publication Number Publication Date
JP2019514895A JP2019514895A (ja) 2019-06-06
JP2019514895A5 true JP2019514895A5 (enExample) 2020-08-20
JP7320947B2 JP7320947B2 (ja) 2023-08-04

Family

ID=56024090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555682A Active JP7320947B2 (ja) 2016-04-19 2017-04-19 新規な免疫原性CD1d結合ペプチド
JP2021200876A Pending JP2022022423A (ja) 2016-04-19 2021-12-10 新規な免疫原性CD1d結合ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021200876A Pending JP2022022423A (ja) 2016-04-19 2021-12-10 新規な免疫原性CD1d結合ペプチド

Country Status (13)

Country Link
US (2) US11485768B2 (enExample)
EP (1) EP3445390A1 (enExample)
JP (2) JP7320947B2 (enExample)
KR (3) KR20220132023A (enExample)
CN (1) CN109069605B (enExample)
AU (2) AU2017252192C1 (enExample)
BR (1) BR112018071466A2 (enExample)
CA (1) CA3019266A1 (enExample)
IL (1) IL262286B2 (enExample)
RU (1) RU2018136760A (enExample)
SG (1) SG11201808710UA (enExample)
WO (1) WO2017182528A1 (enExample)
ZA (1) ZA201806860B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
SG11201908275XA (en) 2017-03-09 2019-10-30 Imcyse Sa Peptides and methods for the treatment of diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CA3138713A1 (en) 2019-05-16 2020-11-19 Imcyse Sa Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine
JP2023525276A (ja) * 2020-05-06 2023-06-15 アンシス・エスア 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
CU20220066A7 (es) * 2020-05-06 2023-06-13 Imcyse Sa Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
AU2021266401A1 (en) * 2020-05-06 2022-12-15 Imcyse Sa Immunogenic peptides with new oxidoreductase motifs
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
AU2022268347C1 (en) * 2021-11-10 2024-04-18 Dana-Farber Cancer Institute, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN114196629B (zh) * 2021-12-23 2024-02-27 珠海贝索细胞科学技术有限公司 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4886782A (en) 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
AU650911B2 (en) 1990-09-27 1994-07-07 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
JPH07502890A (ja) 1991-10-16 1995-03-30 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダーマトファゴイデス(Dermatophagoides)(家ほこりダニ)からの主要なアレルゲンのT細胞エピトープ
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20030152581A1 (en) 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
HK1044040A1 (zh) 1998-11-16 2002-10-04 德克萨斯州立大学董事会 Hiv-特异的t-细胞诱导
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
CA2406621A1 (en) 2000-04-28 2001-11-08 Novozymes A/S Protein variants having modified immunogenicity
EP1294905A1 (en) 2000-06-26 2003-03-26 SmithKline Beecham Biologics SA Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
EP1409650B1 (en) 2001-05-30 2006-04-12 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
CA2458392A1 (en) 2001-10-03 2003-04-17 Unilever Plc Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
AU2003215395A1 (en) 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
GB0324265D0 (en) 2003-10-16 2003-11-19 Medical Res Council Peptide
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Hla−a24拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2008145400A2 (en) 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
US8546137B2 (en) 2007-09-27 2013-10-01 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
US20100330088A1 (en) 2008-02-14 2010-12-30 Jean-Marie Saint-Remy Strategies to prevent and/or treat immunie responses to soluble allofactors
CA2715484C (en) 2008-02-14 2017-04-11 Life Sciences Research Partners Vzw Suppression of immune responses to viral vectors
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
CA2715517C (en) 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US8647879B2 (en) * 2009-08-14 2014-02-11 Polytechnic Institute Of Nyu Peptide probe for rapid and specific detection of β-amyloid aggregation
WO2011120994A1 (en) 2010-03-29 2011-10-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
WO2012069572A1 (en) * 2010-11-25 2012-05-31 Imnate Sarl Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells
ES2869155T3 (es) * 2010-11-25 2021-10-25 Imnate Sarl Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
NZ722352A (en) 2012-02-15 2022-05-27 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte-binding therapeutics
EP2844741A1 (en) * 2012-04-30 2015-03-11 ImCyse SA Methods for induction of antigen-specific regulatory t cells
US9603948B2 (en) * 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents

Similar Documents

Publication Publication Date Title
AU2019250206A1 (en) Novel immunogenic peptides
RU2018136760A (ru) НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ
CO2021004028A2 (es) Proceso para la preparación de composiciones de vacunas
AU2007218649B2 (en) HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
JP2007516966A5 (enExample)
RU2019126232A (ru) Пептиды и способы для лечения диабета
RU2014135406A (ru) Модифицированные эпитопы для усиления ответов cd4+ т-клеток
CN105622749B (zh) 癌抗原辅助肽
JP2017523184A5 (enExample)
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
JP2012506411A5 (enExample)
RU2714117C2 (ru) Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
RU2010110567A (ru) Пептид foxm1 и включающее его медицинское средство
JP2015110588A5 (enExample)
BR112019001656A2 (pt) composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
RU2010110545A (ru) Cdh3-пептид и включающее его лекарственное средство
SA521421371B1 (ar) لقاحات الببتيد
RU2010110564A (ru) Пептид cdca1 и включающее его фармацевтическое средство
KR20140100417A (ko) 경피 투여용 백신 조성물
CA2840954A1 (en) Vaccine composition for transdermal or mucosal administration
JP2019533722A5 (enExample)
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
KR20140100421A (ko) 경피 투여용 wt1 펩티드 암 백신 테이프제
RU2018120387A (ru) Ангиотензин в лечении состояний головного мозга